USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial

EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia

Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024

BioAsia 2024 to focus on data and AI for life sciences

The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others

Natco Pharma and Breckenridge dismissed from antitrust lawsuit

Briefs: NATCO Pharma, Strides Pharma and Aurobindo Pharma

Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia

Former Bayer Pharma CEO Dieter Weinand joins Coya’s Board of Directors

Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business

Ashland collaborates with University of Mississippi School of Pharmacy to sponsor advanced pharmaceutical tableting course

This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries

Global (68M) cardiomyopathies market set to reach $9.63 bn by 2031: GlobalData

The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%